Chemotherapy Resistance: Role of Mitochondrial and Autophagic Components

被引:40
作者
Bahar, Entaz [1 ,2 ,3 ]
Han, Sun-Young [1 ,2 ]
Kim, Ji-Ye [4 ]
Yoon, Hyonok [1 ,2 ]
机构
[1] Gyeongsang Natl Univ, Coll Pharm, Jinju 52828, South Korea
[2] Gyeongsang Natl Univ, Res Inst Pharmaceut Sci, Jinju 52828, South Korea
[3] Gyeongsang Natl Univ, Coll Med, Inst Hlth Sci, Dept Convergence Med Sci & Biochem, Jinju 52727, South Korea
[4] Inje Univ, Ilsan Paik Hosp, Coll Med, Dept Pathol, Goyang 10380, South Korea
基金
新加坡国家研究基金会;
关键词
chemotherapy resistance; mitochondria; mitophagy; ACTIVATED PROTEIN-KINASE; PERMEABILITY TRANSITION PORE; DEPENDENT ANION CHANNEL; DNA-POLYMERASE-GAMMA; BREAST-CANCER CELLS; TUBEROUS SCLEROSIS COMPLEX; HUMAN COLORECTAL-CANCER; GROWTH-FACTOR-RECEPTOR; OVARIAN-CANCER; DRUG-RESISTANCE;
D O I
10.3390/cancers14061462
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Chemotherapy resistance is a common occurrence during cancer treatment that cancer researchers are attempting to understand and overcome. Mitochondria are a crucial intracellular signaling core that are becoming important determinants of numerous aspects of cancer genesis and progression, such as metabolic reprogramming, metastatic capability, and chemotherapeutic resistance. Mitophagy, or selective autophagy of mitochondria, can influence both the efficacy of tumor chemotherapy and the degree of drug resistance. Regardless of the fact that mitochondria are well-known for coordinating ATP synthesis from cellular respiration in cellular bioenergetics, little is known its mitophagy regulation in chemoresistance. Recent advancements in mitochondrial research, mitophagy regulatory mechanisms, and their implications for our understanding of chemotherapy resistance are discussed in this review. Cancer chemotherapy resistance is one of the most critical obstacles in cancer therapy. One of the well-known mechanisms of chemotherapy resistance is the change in the mitochondrial death pathways which occur when cells are under stressful situations, such as chemotherapy. Mitophagy, or mitochondrial selective autophagy, is critical for cell quality control because it can efficiently break down, remove, and recycle defective or damaged mitochondria. As cancer cells use mitophagy to rapidly sweep away damaged mitochondria in order to mediate their own drug resistance, it influences the efficacy of tumor chemotherapy as well as the degree of drug resistance. Yet despite the importance of mitochondria and mitophagy in chemotherapy resistance, little is known about the precise mechanisms involved. As a consequence, identifying potential therapeutic targets by analyzing the signal pathways that govern mitophagy has become a vital research goal. In this paper, we review recent advances in mitochondrial research, mitophagy control mechanisms, and their implications for our understanding of chemotherapy resistance.
引用
收藏
页数:46
相关论文
共 579 条
  • [1] Mini-review on Glycolysis and Cancer
    Akram, M.
    [J]. JOURNAL OF CANCER EDUCATION, 2013, 28 (03) : 454 - 457
  • [2] Mitochondrial Ca2+ Uptake 1 (MICU1) and Mitochondrial Ca2+ Uniporter (MCU) Contribute to Metabolism-Secretion Coupling in Clonal Pancreatic β-Cells
    Alam, Muhammad Rizwan
    Groschner, Lukas N.
    Parichatikanond, Warisara
    Kuo, Liang
    Bondarenko, Alexander I.
    Rost, Rene
    Waldeck-Weiermair, Markus
    Malli, Roland
    Graier, Wolfgang F.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (41) : 34445 - 34454
  • [3] Alberts B., 2002, Molecular Biology of the Cell, P1
  • [4] Role of AMPK-mTOR-Ulk1/2 in the Regulation of Autophagy: Cross Talk, Shortcuts, and Feedbacks
    Alers, Sebastian
    Loeffler, Antje S.
    Wesselborg, Sebastian
    Stork, Bjoern
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2012, 32 (01) : 2 - 11
  • [5] LKB1-dependent signaling pathways
    Alessi, Dario R.
    Sakamoto, Kei
    Bayascas, Jose R.
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2006, 75 : 137 - 163
  • [6] Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis
    Altman, B. J.
    Jacobs, S. R.
    Mason, E. F.
    Michalek, R. D.
    MacIntyre, A. N.
    Coloff, J. L.
    Ilkayeva, O.
    Jia, W.
    He, Y-W
    Rathmell, J. C.
    [J]. ONCOGENE, 2011, 30 (16) : 1855 - 1867
  • [7] From Krebs to clinic: glutamine metabolism to cancer therapy (vol 16, pg 619, 2016)
    Altman, Brian J.
    Stine, Zachary E.
    Dang, Chi V.
    [J]. NATURE REVIEWS CANCER, 2016, 16 (11) : 749 - 749
  • [8] PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
    Alzahrani, Ali S.
    [J]. SEMINARS IN CANCER BIOLOGY, 2019, 59 : 125 - 132
  • [9] Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial
    Amadori, D
    Frassineti, GL
    De Matteis, A
    Mustacchi, G
    Santoro, A
    Cariello, S
    Ferrari, M
    Nascimben, O
    Nanni, O
    Lombardi, A
    Scarpi, E
    Zoli, W
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 49 (03) : 209 - 217
  • [10] Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
    Amaravadi, Ravi K.
    Yu, Duonan
    Lum, Julian J.
    Bui, Thi
    Christophorou, Maria A.
    Evan, Gerard I.
    Thomas-Tikhonenko, Andrei
    Thompson, Craig B.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (02) : 326 - 336